SLC5A2 and diabetic kidney disease: Since it remains to be determined whether early intervention with an SGLT2 inhibitor to control hyperglycemia in an inducible type 1 model of diabetes can prevent the development of advanced diabetic nephropathy especially in conjunction with mild hypertension, the present study examined the effects of chronic administration of an SGLT2 inhibitor, luseogliflozin, given alone and in combination with ACE inhibitor on the development of renal disease following induction of diabetes in STZ-treated Dahl S (Dahl-STZ) rats.